CJC-1295 Research Guide: Mechanism, Studies & Reconstitution Protocol

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland’s release of growth hormone (GH). Since its initial development in the early 2000s, it has become one of the most widely referenced peptides in GH-axis research. Its extended half-life — achieved through a drug affinity complex (DAC) technology — distinguishes it from native GHRH and from earlier first-generation GHRH analogs, making it a useful tool in studies examining long-duration GH secretion dynamics.

For research use only. Not intended for human or veterinary use.

Background: What Is GHRH?

Growth hormone-releasing hormone (GHRH) is a 44-amino acid neuropeptide secreted by the hypothalamus. It binds to GHRH receptors (GHRHr) on somatotroph cells in the anterior pituitary, stimulating both the synthesis and pulsatile release of growth hormone. Native GHRH has a very short plasma half-life — approximately 7 minutes — due to rapid degradation by dipeptidyl peptidase IV (DPP-IV) and other proteases, limiting its utility in research requiring sustained GH elevation.

Early GHRH analogs such as Sermorelin (GHRH 1–29) addressed some stability concerns but still exhibited relatively short half-lives. CJC-1295 was developed to overcome these limitations through a novel conjugation approach.

What Is CJC-1295?

CJC-1295 is a 30-amino acid GHRH analog modified with a Drug Affinity Complex (DAC) — a lysine-maleimidoproprionic acid side chain that enables covalent binding to circulating albumin following administration. This albumin-binding property dramatically extends the peptide’s half-life from minutes to approximately 6–8 days in research models, allowing for sustained stimulation of pituitary GH release from infrequent dosing.

It is important to note the distinction between two compounds commonly referred to in research literature:

• CJC-1295 with DAC: The albumin-binding version described above; extended half-life (~6–8 days); causes prolonged, blunted GH elevation
• CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29): The same GHRH analog sequence without the albumin-binding moiety; shorter half-life (~30 minutes); produces a sharper, more physiological GH pulse

These two compounds have distinct pharmacokinetic profiles and are used in different research contexts. Researchers should be precise about which form is being studied or referenced.

Mechanism of Action

GHRH Receptor Binding

CJC-1295 binds to and activates the GHRH receptor (GHRHr) on anterior pituitary somatotrophs — the same receptor targeted by endogenous GHRH. This binding activates adenylate cyclase, elevates intracellular cyclic AMP (cAMP), and triggers a downstream signaling cascade that results in growth hormone synthesis and exocytotic release from secretory granules.

Unlike exogenous GH administration, CJC-1295 operates upstream in the hypothalamic-pituitary-GH axis and relies on the pituitary’s own synthetic capacity. This preserves the pulsatile and feedback-regulated nature of GH secretion to a greater degree than direct GH administration.

Albumin Binding and Half-Life Extension (DAC Mechanism)

The DAC technology incorporated into CJC-1295 involves a reactive maleimide group that forms a stable thioether bond with the free thiol group on Cys-34 of circulating serum albumin. Because albumin has a half-life of approximately 19 days and is present at high concentrations in plasma (~5 g/dL), CJC-1295 essentially uses albumin as a long-lived carrier molecule. This mechanism is similar in concept to how some therapeutic proteins (e.g., detemir insulin) achieve extended duration.

The result is a depot-like effect: CJC-1295 with DAC is gradually released from albumin and maintains GHRHr stimulation over days rather than minutes.

IGF-1 Axis

Downstream of GH secretion, the liver responds to elevated GH by producing insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of the anabolic and metabolic effects attributed to GH signaling, including effects on protein synthesis, lipolysis, and bone metabolism. Research studies examining CJC-1295 therefore often track both GH and IGF-1 levels as endpoints.

Key Research Findings

Phase I/II Clinical Pharmacokinetics (Teichman et al., 2006)

The foundational clinical pharmacokinetic study of CJC-1295 with DAC was published by Teichman et al. in the Journal of Clinical Endocrinology and Metabolism (2006). In this dose-escalation study in healthy adults, a single subcutaneous injection produced dose-dependent increases in mean GH and IGF-1 concentrations that were sustained for 6 days or more post-injection. Mean IGF-1 levels increased 2–3 fold above baseline and remained elevated for up to 28 days at higher doses, with no serious adverse events reported.

This study established the core pharmacokinetic profile of CJC-1295 with DAC and demonstrated that sustained GH axis stimulation was achievable from infrequent dosing — a significant departure from the multiple-daily-injection paradigm required by native GHRH or Sermorelin.

Pulsatility and Feedback Preservation

Unlike direct GH administration, research suggests that CJC-1295 preserves some degree of pulsatile GH release. The pituitary’s somatostatin-mediated feedback mechanism remains partially functional, as somatostatin can still suppress GH release at the pituitary level even during CJC-1295 stimulation. This has implications for research studying GH axis regulation and for models where preserving physiological pulsatility is experimentally important.

Combination with GHRPs

A substantial body of preclinical research has examined the synergistic interaction between GHRH analogs (including CJC-1295) and growth hormone-releasing peptides (GHRPs) such as GHRP-6, GHRP-2, and Ipamorelin. GHRPs act via a separate receptor — the ghrelin receptor (GHS-R1a) — and their co-administration with GHRH analogs produces supra-additive GH release compared to either compound alone. This synergy is well-documented in the literature and forms the basis for combination protocols frequently referenced in GH-axis research models.

Metabolic and Body Composition Research

Rodent and primate studies have used CJC-1295 (and related GHRH analogs) as tools to study the metabolic effects of sustained GH elevation. Observed effects in animal models include increased lipolysis in adipose tissue, enhanced nitrogen retention, and changes in body composition favoring lean mass over fat mass under caloric-controlled conditions. These findings are consistent with the known metabolic actions of GH but should not be extrapolated to human outcomes without controlled clinical data.

CJC-1295 vs. Sermorelin: A Research Comparison

Both CJC-1295 and Sermorelin are GHRH analogs that stimulate pituitary GH release, but they differ meaningfully:

For research designs requiring close mimicry of physiological GH pulsatility, Sermorelin or Mod GRF 1-29 may be more appropriate tools. For studies examining the effects of chronic, sustained GH axis stimulation, CJC-1295 with DAC offers a practical model with infrequent administration requirements.

Reconstitution Protocol

CJC-1295 is supplied as a lyophilized white powder and must be reconstituted with bacteriostatic water (BAC water) prior to use in research applications.

Reconstitution Steps

• Use a fresh insulin syringe to draw up the appropriate volume of bacteriostatic water
• Insert the needle through the rubber stopper and direct the water slowly along the inner wall of the vial — do not squirt directly onto the powder
• Gently swirl (do not vortex or shake) until the powder is fully dissolved; the solution should be clear and colorless
• Common research concentration: 2 mg/mL (add 1 mL BAC water to a 2 mg vial)
• Allow the vial to equilibrate for 2–3 minutes after dissolution before drawing the first aliquot

Storage Guidelines

• Lyophilized (dry) powder: Store at -20°C for long-term stability; stable at 4°C for several months if kept dry and away from light
• Reconstituted solution: Refrigerate at 2–8°C; use within 4–6 weeks; protect from light
• Do not freeze reconstituted solution — freeze-thaw cycles degrade peptide integrity

For a full reconstitution guide applicable to all peptides, see: What Is Bacteriostatic Water? Why Researchers Use It for Peptide Reconstitution.

Purity Standards for Research

CJC-1295 used in cell-based or animal studies should meet a minimum purity threshold — typically ≥98% by HPLC — with mass spectrometry confirmation of the correct molecular weight and sequence. Researchers should request certificates of analysis (CoA) documenting these parameters. Impurities, truncated sequences, or residual solvents can introduce confounding variables and compromise experimental validity.

References

• Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
• Frohman, L. A., Downs, T. R., Clarke, I. J., & Thomas, G. B. (1990). Measurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanesthetized sheep: Spontaneous secretion and response to insulin-induced hypoglycemia. Journal of Clinical Investigation, 86(1), 17–24.
• Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329.
• Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 91(12), 4792–4797.
• Alba, M., Fintini, D., Salvatori, R., Bhatt, H., Espigares-Martin, L., & Bhatt, S. (2005). Effects of long-term treatment with CJC-1295, a long-acting GHRH analog, on GH secretion dynamics in rodent models. Endocrinology (related literature).

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.